A recently published study by Narayan et al. [44] provided evidence that the upregulation of PP2A and downregulation of the PI3K/Akt pathway members (AKT1, mTOR, 4EBP1, and p21) can be beneficial for the management of patients with CRC. The gene discussed is MTOR; the disease is colorectal carcinoma.